The slow start gives the body time to adjust to the medication and minimizes side effects
While all GLP-1 drugs influence appetite and metabolism, only some (like semaglutide and tirzepatide) are FDA-approved specifically for weight management
You must be willing to change ingrained habits, accept new challenges You confront problems, even uncomfortable or scary ones, rather than ignoring them until its too late. Gulp

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

Compounded vs Brand-Name Semaglutide: What Is the Difference
Organic Antioxidants & Botanicals Calm inflammation, protect against oxidative stress, and enhance skin clarity